Compare Incyte Corporation (INCY) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Orion Office REIT Inc — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Orion Office REIT Inc trades at $2.65 (market cap $150.60M). The key difference: Incyte Corporation is far larger — about 153.5× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.02% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | ONL | |
|---|---|---|
Market Cap | $23.11B | $150.60M |
Sector | Health | Real Estate |
52-Week High | $118.52 | $3.04 |
52-Week Low | $67.38 | $1.93 |
Enterprise Value | $19.13B | $634.25M |
Dividend Yield | — | 3.02% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
